04/16/2026 | Companies

6MW5311, acute myeloid leukemia, AML, biopharmaceuticals, biotechnology, bispecific antibody, cancer research, CD3, chronic myelomonocytic leukemia, clinical trials, CMML, cytotoxicity, drug development, FDA, hematologic malignancies, immune synapse, immunotherapy, IND application, LILRB4, Mabwell, MM, multiple myeloma, NMPA, oncology, preclinical studies, stem cell transplantation, steric hindrance, T cell engager, targeted therapy, TCE technology, tumor inhibition